PeproMene Bio's Groundbreaking Publication in The Lancet Showcases Promising CAR T-Cell Therapy for B-Cell Lymphomas

PeproMene Bio's Groundbreaking Publication in The Lancet

PeproMene Bio, Inc. has recently made headlines with the publication of its Phase 1 clinical trial results in The Lancet, one of the most esteemed medical journals globally. This significant research provides insights into the effectiveness of PMB-CT01, a first-in-class targeted CAR T-cell therapy aimed at treating patients suffering from relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL).

Highlighting the Trial's Success

The recent publication reveals striking outcomes that include durable complete responses among patients, particularly those who have previously undergone CD19-directed therapies. An impressive 80% of the nine patients treated achieved a complete response (CR), which marks a notable improvement from earlier treatment options. Notably, this includes four out of six patients who experienced disease progression after conventional CD19 CAR T-cell therapies.

These responses persisted with no recorded relapses during the data cutoff period, with the longest lasting complete response extending for an impressive 35 months. This demonstrates the potential for PMB-CT01 to not only provide remarkable responses but also suggest a likely avenue for cure in challenging cases of B-cell lymphoma.

Safety Profile of PMB-CT01

Beyond the impressive efficacy, the therapy showcases a favorable safety profile, with all reported cytokine release syndrome (CRS) events classified as Grade 1, along with two isolated Grade 1 incidents of immune effector cell-associated neurotoxicity syndrome (ICANS). This remarkably safe profile of PMB-CT01 indicates the possibility of outpatient administration, which could significantly improve patient access—especially for those underserved populations who are currently disadvantaged in their ability to receive treatment.

Expansion of Clinical Trials

In light of these encouraging outcomes, PeproMene Bio has expanded its Phase 1 trial from a single clinical location at City of Hope, a notable cancer research and treatment institution, to include several additional medical centers across the United States. The expansion signifies a critical growth in the efforts to evaluate PMB-CT01 and its application in combating B-cell lymphomas effectively.

Furthermore, during the expansion phase, the first patient treated—who previously had a triple-hit high-grade B-cell lymphoma after progression on a CD19-directed CAR T-cell therapy—also achieved complete response at the first disease assessment.

Insights From Clinical Experts

Larry W. Kwak, M.D., Ph.D., the scientific founder of PeproMene Bio, emphasized the importance of the publication, stating, “Publishing these peer-reviewed data in The Lancet represents a significant recognition of this novel therapy.” He further highlighted that absence of relapses supports the notion that PMB-CT01 could represent a breakthrough in CAR T-cell options aimed at blood cancers that had previously been deemed incurable.

Complementing Kwak's sentiments, Stephen Forman, M.D., the paper’s co-author and director of the Hematologic Malignancies Institute at City of Hope, recognized the significance of these early results for patients whose diseases have progressed after previous therapies targeting CD19 or CD20. The institution remains committed to advancing this clinical trial as the coordinating center and primary manufacturing site.

Support and Funding for Continued Development

The Institute for Follicular Lymphoma Innovation (IFLI) has also shown strong support for PeproMene Bio, pledging up to $11 million to propel the clinical development of PMB-CT01 specifically for patients with relapsed or refractory follicular lymphoma. Dr. Mehrdad Mobasher, an Executive Partner at IFLI, aptly stated that “for patients whose lymphoma returns after CD19-directed CAR T-cell therapy, a new target can mean a new chance,” further underscoring the significant potential of this research.

Conclusion

As PeproMene Bio continues to navigate the clinical landscape, the findings in The Lancet showcase not only a promising therapy in PMB-CT01 but also raise hopes for patients with difficult-to-treat B-cell lymphomas. The advancement toward outpatient administration could also transform access to care for various patient groups. With ongoing support and expanding clinical trials, the future looks brighter for patients battling these challenging conditions.